Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be at least 18 years of age at the time of the screening.~* Participant may be male or female.~* Participant has a confirmed diagnosis of ITP according to the 2019 International Working Group assessment at screening.~* Participant who didn't respond to eltrombopag retreatment (75mg by mouth once a day for 14 days) after eltrombopag previous treatment inefficient or relapsed (platelet count below 30 × 10\^9/L or below 2-fold increase from baseline platelet count, or bleeding).~* Bone marrow biopsy is performed in participants over 60 years to exclude hematological malignancies.~Exclusion Criteria:~* Participant has evidence of a secondary cause of immune thrombocytopenia (e.g. leukemia, lymphoma, common variable immune-deficiency, systemic lupus erythematosus, autoimmune thyroid disease, past medical history of untreated H. pylori infection) or to drug treatments (e.g. heparin, quinine, antimicrobials, anticonvulsants) or participant has a multiple immune cytopenia, e.g. Evan's syndrome.~* Participant has clinically life-threatening bleeding (e.g. central nervous system bleeding, menorrhagia with significant drop in hemoglobin). Participant has a history of coagulopathy disorders other than ITP.~* Participant has a history of arterial or venous thromboembolism (e.g. stroke, transient ischemic attach, myocardial infarction, deep vein thrombosis or pulmonary embolism) within the 6 months prior to randomization or requires anticoagulant treatment.~* Participant has 12-lead ECG with changes considered to be clinically significant upon medical review at baseline.~* Participant has severe renal impairment (glomerular filtration rate less than 45ml/min/1.73 m2).~* Participant has 3 × upper limit of normal of any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.~* Participant has received corticosteroids, rh-TPO, romiplostim, or immunosuppression within 4 weeks before screening.~* Participant with any of the following conditions: severe immunodeficiency, active or previous malignancy, human immunodeficiency virus (HIV), hepatitis B or C virus infection, pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination group (Type: EXPERIMENTAL): Eltrombopag plus diacerein
- Monotherapy group (Type: PLACEBO_COMPARATOR): Eltrombopag monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).